Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.53 |
| ▸ | CA2 | P00918 | 8/20 | 0.53 |
| ▸ | CA9 | Q16790 | 8/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 8/20 | 0.53 |
| ▸ | DRD1 | P21728 | 4/20 | 0.50 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD5 | P21918 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5516099 | 0.81 | ESR1 (0.59) | ESR1ESR2 | |
| SCHEMBL6715265 | 0.81 | CA1 (0.62) | CA1CA2CA9CA14DRD1 | |
| SCHEMBL5518169 | 0.81 | CA1 (0.51) | CA1CA2CA9CA14DRD1 | |
| SCHEMBL5519137 | 0.81 | DRD1 (0.60) | CA1CA2CA9CA14DRD1 | |
| SCHEMBL5512737 | 0.80 | CA1 (0.63) | CA1CA2CA9CA14DRD1 | |
| SCHEMBL6328715 | 0.80 | ESR1 (0.47) | DRD1ESR1ESR2 | |
| SCHEMBL3778328 | 0.78 | CA1 (0.48) | CA1CA2CA9CA14DRD1 | |
| SCHEMBL5518952 | 0.78 | DRD1 (0.51) | CA1CA2CA9CA14DRD1 | |
| SCHEMBL6713488 | 0.78 | ESR1 (0.61) | CA1CA2CA9CA14DRD1 | |
| Hydrochloric Acid SCHEMBL3767343 | 0.77 | ESR1 (0.57) | CA1CA2CA9CA14DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7256201-B2 | Selective estrogen receptor-β ligands | ASTRAZENECA AB (SE) | 2007-08-14 | — | — | US | disclosed |
| US-20050101584-A1 | Selective estrogen receptor-beta ligands | ASTRAZENECA AB (SE) | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101584-A1 | Selective estrogen receptor-beta ligands | ESR2, ESRRA, ESRRB | CA1 3708/4885CA2 4743/4885CA9 4694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.